The use of antibiotics in meat production is a major contributor to one of the biggest threats facing human health in the 21st century: antibiotic resistance. Finding a solution to this requires us to start taking responsibility for our actions. While one person eating meat has an imperceptible effect on antibiotic resistance, multiply that by millions of people around the world and you have a global crisis. Continue reading
The New York Times just ran a fairly lengthy article that reported the use of psilocybin, a hallucinogenic drug, in a controlled experiment aimed at reducing anxiety and depression in cancer patients. (http://www.nytimes.com/2016/12/01/health/hallucinogenic-mushrooms-psilocybin-cancer-anxiety-depression.html?hp&action=click&pgtype=Homepage&clickSource=story-heading&module=first-column-region®ion=top-news&WT.nav=top-news)
A few days earlier the New York Times ran a story on trials using MDMA (i.e., ecstasy) to treat post traumatic stress disorder. (http://www.nytimes.com/2016/11/29/us/ptsd-mdma-ecstasy.html)
Why are these stories news? Continue reading
Guest Post: Mind the accountability gap: On the ethics of shared autonomy between humans and intelligent medical devices
Guest Post by Philipp Kellmeyer
Imagine you had epilepsy and, despite taking a daily cocktail of several anti-epileptic drugs, still suffered several seizures per week, some minor, some resulting in bruises and other injuries. The source of your epileptic seizures lies in a brain region that is important for language. Therefore, your neurologist told you, epilepsy surgery – removing brain tissue that has been identified as the source of seizures in continuous monitoring with intracranial electroencephalography (iEEG) – is not viable in your case because it would lead to permanent damage to your language ability.
There is however, says your neurologist, an innovative clinical trial under way that might reduce the frequency and severity of your seizures. In this trial, a new device is implanted in your head that contains an electrode array for recording your brain activity directly from the brain surface and for applying small electric shocks to interrupt an impending seizure.
The electrode array connects wirelessly to a small computer that analyses the information from the electrodes to assess your seizure risk at any given moment in order to decide when to administer an electric shock. The neurologist informs you that trials with similar devices have achieved a reduction in the frequency of severe seizures in 50% of patients so that there would be a good chance that you benefit from taking part in the trial.
Now, imagine you decided to participate in the trial and it turns out that the device comes with two options: In one setting, you get no feedback on your current seizure risk by the device and the decision when to administer an electric shock to prevent an impending seizure is taken solely by the device.
This keeps you completely out of the loop in terms of being able to modify your behaviour according to your seizure risk and – in a sense – relegates some autonomy of decision-making to the intelligent medical device inside your head.
In the other setting, the system comes with a “traffic light” that signals your current risk level for a seizure, with green indicating a low, yellow a medium, and red a high probability of a seizure. In case of an evolving seizure, the device may additionally warn you with an alarm tone. In this scenario, you are kept in the loop and you retain your capacity to modify your behavior accordingly, for example to step from a ladder or stop riding a bike when you are “in the red.”
Written by Dr Christopher Gyngell
This article originally appeared on the OMS website
The Nuffield Council of Bioethics released a report last Friday outlining the key ethical issues raised by genome editing technologies.
Genome editing (GE) is a powerful, and extremely rapidly developing technology. It uses engineered enzymes to make precise, controlled modification to DNA. It has the potential to radically transform many industries, including medicine, agriculture and ecology. Despite only being developed in the past few years’, GE has already been used to create malaria-fighting mosquitoes, drought resistant wheat, hornless cows and cancer killing immune cells. The potential applications of GE in a decade are difficult to imagine. It raises a wide range of ethical issues that require careful scrutiny. Continue reading
This article was originally published in The Conversation
Written by Julian Savulescu Sir Louis Matheson Distinguishing Visiting Professor at Monash University,
Uehiro Professor of Practical Ethics, University of Oxford
Connor Rochford Medical Student, Monash University
Daniel D’Hotman Medical Student, Monash University
Drug analysis would be a safe, ethical and cost-effective way to reduce harm to young people. Shutterstock
At the Stereosonic festival last year, Sylvia Choi died after consuming a contaminated ecstasy tablet. Unfortunately Sylvia’s narrative is all too familiar – a bright future extinguished at a music festival that will be remembered for all the wrong reasons.
This summer, many young people will also choose to consume various illegal substances in pursuit of a good time. Regardless of their personal choice to break the law, most would agree that they should not have to die for it. Continue reading
Professor Julian Savulescu has recently published an article on the treatment of Human-Pig Chimera in the online Aeon Magazine. To read the full article and join in the conversation please follow this link: http://bit.ly/29NUj1c Professor Savulescu has written on this topic in the Practical Ethics in the News blog previously: http://blog.practicalethics.ox.ac.uk/2016/06/organ-mules/.
Cross Post: Next time you ask the doctor for some antibiotics – consider whether you’re being immoral
Written by Alberto Giubilini, Postdoctoral Research Fellow, Oxford Uehiro Centre for Practical Ethics
This article was originally published in The Conversation
Antimicrobial resistance is the ability of microorganisms causing infections to survive exposure to antimicrobial drugs such as antibiotics. This is considered by some to be a slowly emerging disaster. According to the recently released Review on Antimicrobial Resistance commissioned by the UK government, by 2050 some 10m lives a year will be at risk because of drug resistant infections.
Event: St Cross Special Ethics Seminar: The role of therapeutic optimism in recruitment to a clinical trial: an empirical study, presented by Dr Nina Hallowell
On Thursday 12 May 2016, Dr Nina Hallowell delivered the first St Cross Special Ethics Seminar of Trinity Term. The talk is available to listen to here http://media.philosophy.ox.ac.uk/uehiro/TT16_STX_Hallowell.mp3
Title: The role of therapeutic optimism in recruitment to a clinical trial: an empirical study Continue reading
Written by Simon Beard, Research Associate at the Center for the Study of Existential Risk, University of Cambridge
How can we study the pathogens that will be responsible for future global pandemics before they have happened? One way is to find likely candidates currently in the wild and genetically engineer them so that they gain the traits that will be necessary for them to cause a global pandemic.
Such ‘Gain of Function’ research that produces ‘Potential Pandemic Pathogens’ (GOF-PPP for short) is highly controversial. Following some initial trails looking at what kinds of mutations were needed to make avian influenza transmissible in ferrets, a moratorium has been imposed on further research whilst the risks and benefits associated with it are investigated. Continue reading
Cross Post: Ideas for Australia: Rethinking funding and priorities in IVF – should the state pay for people to have babies?
Written by Professor Julian Savulescu and Professor Kelton Tremellen
This is a cross posting of an article which was originally published at The Conversation
How much should the state spend on helping people to have children? At present, government support for infertility treatment is approximately A$240 million a year. The success of fertility treatments such as IVF is good if you are under 35 years of age, but once a woman hits 40 it plummets, falling to an almost futile one-in-80 chance of producing a baby for women 45 years and older. This raises the question – is IVF a cost-effective use of taxpayers’ money? And what about for older women?
Decisions about funding are usually made on grounds of cost-effectiveness. In Australia, the cost-effectiveness threshold is about A$40,000 per “QALY”. A QALY is a quality adjusted life year. Thus the government will spend, for example, A$40,000 to add a year of full health, or improve the quality of life by 10% for 10 years.
Is IVF cost-effective? It depends on how we measure it. Continue reading